세계의 유방암 코어 니들 생검 시장 - 규모, 점유율, 동향 분석 보고서 : 기술별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Breast Cancer Core Needle Biopsy Market Size, Share & Trends Analysis Report By Technology, By End-use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,590,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,034,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,922,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

유방암 코어 니들 생검 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계 유방암 코어 니들 생검 시장 규모는 2030년까지 11억 5,000만 달러에 달할 것으로 추정되며, 2025-2030년 동안 CAGR 4.6%로 성장할 전망입니다. 시장 성장의 주요 요인은 유방암 유병률 증가, 정기적인 유방 조영술 검진의 권장의 보급, 개인의 의식 증가, 이 부문에서 실시된 광범위한 조사 연구 등입니다. 이러한 요인이 종합적으로 유방암 코어 니들 생검 수요 증가와 채용에 기여하고 있어 향후 몇 년간 현저한 성장의 길을 열 것입니다.

게다가, 영상 및 생검 기술의 끊임없는 진보는 산업 확대에 기여하고 있습니다. 조기 발견과 진단이 환자의 예후를 개선하는 중요한 역할에 대한 인식이 높아지고 있습니다. 코어 니들 생검은 기존의 개복 수술을 통한 생검과 비교하여 침습성 감소, 회복 시간 단축, 비용 효과 등 명확한 이점을 설명합니다.

조기 발견·진단 수요가 계속 증가하는 가운데 유방암 코어 니들 생검 시장은 큰 성장이 예상되고 있습니다. 이 부문의 혁신적인 연구의 최근 예로는 스페인 IMIM(Hospital del Mar Medical Research Institute)의 연구자들이 2022년에 European Radiology 잡지에 발표한 조사 결과와 같이 병변의 시각화에 MRI 기술을 이용한 조영 유방 조영술 유방 생검의 사용을 들 수 있습니다.

COVID-19의 대유행은 유방암 코어 니들 생검 시장에서의 과제인 동시에 새로운 기회도 가져왔습니다. 불필요한 치료 지연은 진단률 감소와 핵심 바늘 생검 수요 감소로 이어졌습니다. 그러나 팬데믹은 조기 발견의 중요성을 강조하고 의료 제공업체에게 검진과 생검을 우선하게 하여 수요가 부활했습니다.

유방암 핵심 바늘 생검 시장 보고서 하이라이트

• 초음파 기반 유방 생검 부문은 2024년 41.9%의 최대 판매 점유율을 차지했습니다. 이 부문의 이점은 초음파 가이드 하 생검의 뚜렷한 이점으로 인한 선호도 증가로 인한 것입니다.
• 병원 및 진단 실험실 부문은 2024년에 60.0%의 최고 수익 점유율을 획득했습니다.
• 학술기관 및 연구기관 부문은 유방암 코어 니들 생검 산업에서 2025-2030년 동안 CAGR 4.4%의 비약적인 성장이 예측되고 있습니다.
• 북미 유방암 코어 니들 생검 산업은 2024년 46.26%의 매출 점유율을 차지했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 유방암 코어 니들 생검 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 유방암 코어 니들 생검 시장 분석 도구
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 유방암 코어 니들 생검 시장 : 기술별, 추정·동향 분석

• 기술 시장 점유율, 2024년과 2030년
• 부문 대시보드
• 기술에 의한 세계의 유방암 코어 니들 생검 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
  • MRI 유방 생검
  • 초음파 유방 생검
  • 유방 조영술(정위) 유방 생검
  • CT 유방 생검
  • 기타 이미지 기반 유방 생검

제5장 유방암 코어 니들 생검 시장 : 최종 용도별, 추정·동향 분석

• 최종 용도 시장 점유율, 2024년과 2030년
• 부문 대시보드
• 최종 용도에 의한 세계의 유방암 코어 니들 생검 시장 전망
• 2018-2030년 시장 규모와 예측과 동향 분석
  • 병원 & 진단 실험실
  • 제약 및 바이오테크놀러지 기업
  • 학술연구기관

제6장 유방암 코어 니들 생검 시장 :지역별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모와 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 상황
  • 주요 기업의 시장 점유율 분석, 2024년
  • Intact Medical Corporation
  • Ethicon Surgical Technologies
  • Gallini SRL
  • Leica Biosystems Nussloch GmbH
  • Hologic, Inc
  • Argon Medical Devices
  • Encapsule Medical Devices LLC
  • Cook Medical Incorporated
  • Becton, Dickinson and Company
  • CR Bard, Inc.

JHS

영문 목차

영문목차

Breast Cancer Core Needle Biopsy Market Growth & Trends:

The global breast cancer core needle biopsy market size is estimated to reach USD 1.15 billion by 2030, registering to grow at a CAGR of 4.6% from 2025 to 2030 according to a new report by Grand View Research, Inc. The market growth is primarily propelled by factors such as the increasing prevalence of breast cancer, the widespread recommendations for regular mammography screenings, rising awareness among individuals, and extensive research studies conducted in this field. These factors collectively contribute to the rising demand and adoption of breast cancer core needle biopsy procedures, paving the way for significant growth in the coming years.

Additionally, continuous advancements in imaging technologies and biopsy techniques contribute to the expansion of the industry. There is a growing recognition of the crucial role that early detection and diagnosis play in improving patient outcomes. Core needle biopsies offer distinct advantages over traditional open surgical biopsies, including reduced invasiveness, quicker recovery time, and cost-effectiveness.

As the demand for early detection and diagnosis continues to rise, the market for breast cancer core needle biopsy is expected to witness significant growth. A recent example of innovative research in this field involves the use of contrast-mammography-guided breast biopsies that utilize MRI technology for lesion visualization, as demonstrated by researchers at the IMIM (Hospital del Mar Medical Research Institute) in Spain, in 2022 with the findings published in the journal European Radiology.

The COVID-19 pandemic has both challenged and opened new opportunities in the breast cancer core needle biopsy market. Delays in non-essential procedures have led to a decrease in diagnosis rate and demand for core needle biopsies. However, the pandemic has emphasized the importance of early detection, leading healthcare providers to prioritize screenings and biopsies, resulting in a resurgence in demand.

Breast Cancer Core Needle Biopsy Market Report Highlights:

• The ultrasound-based breast biopsy segment accounted for the largest revenue share of 41.9% in 2024. The segment dominance can be attributed to the growing preference for ultrasound-guided biopsies due to their notable advantages.
• The hospitals & diagnostic laboratories segment captured the highest revenue share of 60.0% in 2024.
• The academic & research institutes segment is predicted to grow at an exponential CAGR of 4.4% from 2025 to 2030 in the breast cancer core needle biopsy industry.
• North America breast cancer core needle biopsy industry dominated and accounted for a 46.26%of revenue share in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology
  • 1.2.2. End use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Technology outlook
  • 2.2.2. End use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Breast Cancer Core Needle Biopsy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing prevalence of breast cancer
    • 3.2.1.2. Advancement in imaging technologies and biopsy techniques
    • 3.2.1.3. Rising inclination towards minimally invasive procedures
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of core needle biopsy procedures
    • 3.2.2.2. Limited expertise and training
• 3.3. Breast Cancer Core Needle Biopsy Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Breast Cancer Core Needle Biopsy Market: Technology Estimates & Trend Analysis

• 4.1. Technology Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Breast Cancer Core Needle Biopsy Market by Technology Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. MRI-Based Breast Biopsy
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 4.4.2. Fermentation Ultrasound-Based Breast Biopsy
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Mammography-Based (Stereotactic) Breast Biopsy
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. CT-Based Breast Biopsy
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Other Image-Based Breast Biopsy
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Breast Cancer Core Needle Biopsy Market: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Breast Cancer Core Needle Biopsy Market by End Use Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Hospitals & Diagnostic Laboratories
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 5.4.2. Pharmaceutical & Biotechnology companies
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Academic & Research Institutes
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Breast Cancer Core Needle Biopsy Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Target Disease Prevalence
    • 6.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Target Disease Prevalence
    • 6.5.2.4. Competitive scenario
    • 6.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Mexico
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Target Disease Prevalence
    • 6.5.3.4. Competitive scenario
    • 6.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Target Disease Prevalence
    • 6.6.1.4. Competitive scenario
    • 6.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Target Disease Prevalence
    • 6.6.2.4. Competitive scenario
    • 6.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Target Disease Prevalence
    • 6.6.3.4. Competitive scenario
    • 6.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Target Disease Prevalence
    • 6.6.4.4. Competitive scenario
    • 6.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Target Disease Prevalence
    • 6.6.5.4. Competitive scenario
    • 6.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Norway
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Target Disease Prevalence
    • 6.6.6.4. Competitive scenario
    • 6.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/ reimbursement structure
    • 6.6.7.3. Target Disease Prevalence
    • 6.6.7.4. Competitive scenario
    • 6.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Denmark
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/ reimbursement structure
    • 6.6.8.3. Target Disease Prevalence
    • 6.6.8.4. Competitive scenario
    • 6.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Target Disease Prevalence
    • 6.7.1.4. Competitive scenario
    • 6.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Target Disease Prevalence
    • 6.7.2.4. Competitive scenario
    • 6.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Target Disease Prevalence
    • 6.7.3.4. Competitive scenario
    • 6.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Target Disease Prevalence
    • 6.7.4.4. Competitive scenario
    • 6.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Target Disease Prevalence
    • 6.7.5.4. Competitive scenario
    • 6.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/ reimbursement structure
    • 6.7.6.3. Target Disease Prevalence
    • 6.7.6.4. Competitive scenario
    • 6.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Target Disease Prevalence
    • 6.8.1.4. Competitive scenario
    • 6.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Target Disease Prevalence
    • 6.8.2.4. Competitive scenario
    • 6.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/ reimbursement structure
    • 6.9.1.3. Target Disease Prevalence
    • 6.9.1.4. Competitive scenario
    • 6.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/ reimbursement structure
    • 6.9.2.3. Target Disease Prevalence
    • 6.9.2.4. Competitive scenario
    • 6.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/ reimbursement structure
    • 6.9.3.3. Target Disease Prevalence
    • 6.9.3.4. Competitive scenario
    • 6.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/ reimbursement structure
    • 6.9.4.3. Target Disease Prevalence
    • 6.9.4.4. Competitive scenario
    • 6.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key company market share analysis, 2024
  • 7.3.2. Intact Medical Corporation
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Product benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. Ethicon Surgical Technologies
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Product benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. Gallini SRL
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Leica Biosystems Nussloch GmbH
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Hologic, Inc
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Argon Medical Devices
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Encapsule Medical Devices LLC
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Cook Medical Incorporated
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Becton, Dickinson and Company
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. C.R. Bard, Inc.
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives

관련자료